Valuation : MannKind Corporation

Market Cap 127.01Cr 109.44Cr 102.61Cr 94Cr 176.46Cr 12TCr 177.02Cr 1.22TCr 475Cr 6.13TCr 476.85Cr 466.48Cr 20TCr P/E 2026 *
-21.6x
P/E 2027 * -3,160x
Enterprise Value 127.01Cr 109.44Cr 102.61Cr 94Cr 176.46Cr 12TCr 177.02Cr 1.22TCr 475Cr 6.13TCr 476.85Cr 466.48Cr 20TCr EV / Sales 2026 *
2.86x
EV / Sales 2027 * 2.52x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day-2.71%
1 week-4.82%
Current month+1.02%
1 month+2.60%
3 months+4.77%
6 months+20.43%
Current year-30.34%
1 week 3.93
Extreme 3.93
4.24
1 month 3.63
Extreme 3.63
4.4
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap.
07/08/26 Sell

Director

-39,051 0.0122%
17/07/26 Sell

General Counsel

-24,109 0.0078%
17/07/26 Sell

Director

-52,485 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-2.71%-4.82%-13.94%-15.42% 127.01Cr
-1.59%-3.35%+52.37%+93.70% 6.95TCr
-1.34%-0.75%+48.21%+91.86% 6.5TCr
+0.30%-0.69%+52.56%+10.23% 2.65TCr
-2.35%-5.75%-12.90%+448.54% 2.59TCr
-8.37%-12.43%+2.08%-16.71% 2.56TCr
-0.96%+10.36%+283.06%+436.50% 2.02TCr
-0.51%+0.23%+35.77%-18.70% 2TCr
-1.91%-4.37%+13.28%+535.19% 1.57TCr
-1.47%+0.68%+45.51%+143.08% 1.35TCr
Average -2.09%-2.22%+50.60%+170.83% 2.83TCr
Weighted average by Cap. -1.93%-1.52%+53.42%+150.76%

Financials

2026 *2027 *
Net sales 44Cr 38Cr 36Cr 33Cr 62Cr 4.24TCr 62Cr 425.05Cr 165.84Cr 2.14TCr 166.49Cr 162.86Cr 7.09TCr 50Cr 43Cr 41Cr 37Cr 70Cr 4.82TCr 70Cr 483.15Cr 188.51Cr 2.43TCr 189.24Cr 185.12Cr 8.06TCr
Net income -5.72Cr -4.93Cr -4.62Cr -4.22Cr -7.94Cr -546.46Cr -7.97Cr -55Cr -21Cr -275.85Cr -21Cr -21Cr -914.68Cr 27.12T 23.37T 21.91T 20T 37.68T 25.92L 37.8T 3L 1L 13.08L 1L 99.61T 43.38L
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
28/26/28 $3.950 -2.71% 19,90,144
27/26/27 $4.060 -0.73% 20,68,822
26/26/26 $4.090 -1.68% 17,66,310
25/26/25 $4.160 +2.21% 31,93,655
24/26/24 $4.070 -1.93% 28,12,485
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.950USD
Average target price
7.969USD
Spread / Average Target
+101.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock